Hiva Kolodrubetz, NP, provides an engaging and detailed session on anti-diabetic medications, focusing on safe prescribing and effective management strategies. Highlighting pharmacological mechanisms, A1C goals, and patient-centered care,…
Associate Professor Mike Todorovic, AKA “Dr. Mike”, introduces the endocrine system, explaining how hormones act as chemical messengers released into the bloodstream by cells, tissues, and glands. He…
NEW YORK (Reuters Health) – The combination of niacin and fenofibrate, along with diet and exercise, markedly improves the lipid profile of HIV patients on antiretroviral therapy (ART),…
NEW YORK (Reuters Health) – Even when small, nonfunctioning pancreatic endocrine tumors are likely to be aggressive, and should be removed when they are discovered incidentally, according to…
NEW YORK (Reuters Health) – For patients with type 2 diabetes not controlled with metformin and a sulfonylurea, the choice of an additional agent should be based on…
NEW YORK (Reuters Health) – Cotreatment with an angiotensin-converting enzyme (ACE) inhibitor reduces the risk of diabetes associated with beta blocker treatment, according to a report in the…
NEW YORK (Reuters Health) – For women with anorexia nervosa, weekly risedronate increases spinal bone mineral density over the course of a year. Adding low-dose testosterone does not…
NEW YORK (Reuters Health) – For children and adolescents with conditions that require frequent placement of intravenous lines, administration of 50% nitrous oxide makes the process of IV…
NEW YORK – Hemoglobin A1c (A1C) levels are not sensitive or specific enough to be used to identify children and adolescents with or at risk for diabetes, according…
NEW YORK (Reuters Health) – Insulin resistance substantially curbs the chances of a sustained viral response following standard treatment for chronic hepatitis C virus (HCV) infection, according to…
NEW YORK (Reuters Health) – The risk of pancreatic malignancy is increased in patients with diabetes, researchers from Taiwan report in a pre-print version of a study that…
NEW YORK (Reuters Health) – An updated review of medications available for treating type 2 diabetes concludes that metformin continues to have the best benefit-to-harm profile, according to…
